Extracorporeal membrane oxygenation

Source: Wikipedia, the free encyclopedia.

Extracorporeal membrane oxygenation
Veno-arterial (VA) ECMO for cardiac or respiratory failure.jpg
Other namesExtracorporeal life support (ECLS)

Extracorporeal membrane oxygenation (ECMO), also known as extracorporeal life support (ECLS), is an extracorporeal technique of providing prolonged cardiac and respiratory support to persons whose heart and lungs are unable to provide an adequate amount of gas exchange or perfusion to sustain life. The technology for ECMO is largely derived from cardiopulmonary bypass, which provides shorter-term support with arrested native circulation. The device used is a membrane oxygenator, also known as an artificial lung.

ECMO works by temporarily drawing blood from the body to allow artificial oxygenation of the red blood cells and removal of carbon dioxide. Generally, it is used either post-cardiopulmonary bypass or in late-stage treatment of a person with profound heart and/or lung failure, although it is now seeing use as a treatment for cardiac arrest in certain centers, allowing treatment of the underlying cause of arrest while circulation and oxygenation are supported. ECMO is also used to support patients with the acute viral pneumonia associated with COVID-19 in cases where artificial ventilation alone is not sufficient to sustain blood oxygenation levels.

Medical uses

ECMO sketch
ECMO circuit

Guidelines that describe the indications and practice of ECMO are published by the Extracorporeal Life Support Organization (ELSO). Criteria for the initiation of ECMO vary by institution, but generally include acute severe cardiac or pulmonary failure that is potentially reversible and unresponsive to conventional management. Examples of clinical situations that may prompt the initiation of ECMO include the following:[1]

In those with cardiac arrest or cardiogenic shock, it appears to improve survival and good outcomes.[4]

Use in COVID-19 patients

Beginning in early February 2020, doctors in China have increasingly been using ECMO as an adjunct support for patients presenting with acute viral pneumonia associated with SARS-CoV-2 infection (COVID-19) when, with ventilation alone, the blood oxygenation levels still remain too low to sustain the patient.[5] The initial reports indicate that it is assisting in restoring patients' blood oxygen saturation and reducing fatalities among the approximately 3% of severe cases where it has been utilized.[6] For critically ill patients, the mortality rate reduces from around 59–71% with conventional therapy to approximately 46% with extracorporeal membrane oxygenation.[7] A March 2021 Los Angeles Times cover story illustrated the efficacy of ECMO in an extremely challenging COVID patient.[8] In February 2021, three pregnant Israeli women who had "very serious" cases of COVID-19 were given ECMO treatment and it seemed this treatment option would continue.[9]


Early studies had shown survival benefit with use of ECMO for people in acute respiratory failure especially in the setting of acute respiratory distress syndrome.[10][11] A registry maintained by ELSO of nearly 51,000 people that have received ECMO has reported outcomes with 75% survival for neonatal respiratory failure, 56% survival for pediatric respiratory failure, and 55% survival for adult respiratory failure.[12] Other observational and uncontrolled clinical trials have reported survival rates from 50 to 70%.[13][14] These reported survival rates are better than historical survival rates.[15][16][17] Even though ECMO is used for a range of conditions with varying mortality rates, early detection is key to prevent the progression of deterioration and increase survival outcomes.[18]

In the United Kingdom, veno-venous ECMO deployment is concentrated in designated ECMO centers to potentially improve care and promote better outcomes.


Most contraindications are relative, balancing the risks of the procedure versus the potential benefits. The relative contraindications are:

  1. Conditions incompatible with normal life if the person recovers
  2. Preexisting conditions that affect the quality of life (CNS status, end-stage malignancy, risk of systemic bleeding with anticoagulation)
  3. Age and size
  4. Futility: those who are too sick, have been on conventional therapy too long, or have a fatal diagnosis.

Side effects/Complications


A common consequence in ECMO-treated adults is neurological injury, which may include intracerebral hemorrhage, subarachnoid hemorrhage, ischemic infarctions in susceptible areas of the brain, hypoxic-ischemic encephalopathy, unexplained coma, and brain death.[19] Bleeding occurs in 30 to 40% of those receiving ECMO and can be life-threatening. It is due to both the necessary continuous heparin infusion and platelet dysfunction. Meticulous surgical technique, maintaining platelet counts greater than 100,000/mm3, and maintaining the target activated clotting time reduce the likelihood of bleeding.[citation needed]


Heparin-induced thrombocytopenia (HIT) is increasingly common among people receiving ECMO. When HIT is suspected, the heparin infusion is usually replaced by a non-heparin anticoagulant.[20]

There is retrograde blood flow in the descending aorta whenever the femoral artery and vein are used for VA (Veno-Arterial) ECMO. Stasis of the blood can occur if left ventricular output is not maintained, which may result in thrombosis.[citation needed]

Bridge to assist device

In VA ECMO, those whose cardiac function does not recover sufficiently to be weaned from ECMO may be bridged to a ventricular assist device (VAD) or transplant. A variety of complications can occur during cannulation, including vessel perforation with bleeding, arterial dissection, distal ischemia, and incorrect location (e.g., venous cannula placed within the artery), but these events occur highly infrequently.[citation needed]


Preterm infants are at unacceptably high risk for intraventricular hemorrhage (IVH) if administered ECMO at a gestational age less than 32 weeks.[21]


The prevalence of hospital-acquired infections during ECMO is 10-12% (higher compared to other critically ill patients). Coagulase-negative staphylococci, Candida spp., Enterobacteriaceae and Pseudomonas aeruginosa are the most frequently involved pathogens. ECMO patients display a high incidence of ventilator-associated pneumonia (24.4 cases/1000 ECMO days), with a major role played by Enterobacteriaceae. The infectious risk was shown to increase along the duration of the ECMO run, which is the most important risk factor for the development of infections. Other ECMO-specific factors predisposing to infections include the severity of illness in ECMO patients, the high risk of bacterial translocation from the gut and ECMO-related impairment of the immune system. Another important issue is the microbial colonisation of catheters, ECMO cannulae and the oxygenator.[22]


Veno-arterial (VA) ECMO for cardiac or respiratory failure.[23]
Veno-venous (VV) ECMO for respiratory failure.[23]

There are several forms of ECMO; the two most common are veno-arterial (VA) ECMO and veno-venous (VV) ECMO. In both modalities, blood drained from the venous system is oxygenated outside of the body. In VA ECMO, this blood is returned to the arterial system and in VV ECMO the blood is returned to the venous system. In VV ECMO, no cardiac support is provided.


In veno-arterial (VA) ECMO, a venous cannula is usually placed in the right or left common femoral vein for extraction, and an arterial cannula is usually placed into the right or left femoral artery for infusion.[24] The tip of the femoral venous cannula should be maintained near the junction of the inferior vena cava and right atrium, while the tip of the femoral arterial cannula is maintained in the iliac artery.[24] In adults, accessing the femoral artery is preferred because the insertion is simpler.[24] Central VA ECMO may be used if cardiopulmonary bypass has already been established or emergency re-sternotomy has been performed (with cannulae in the right atrium (or SVC/IVC for tricuspid repair) and ascending aorta).

VA ECMO is typically reserved when native cardiac function is minimal to mitigate increased cardiac stroke work associated with pumping against retrograde flow delivered by the aortic cannula.


In veno-venous (VV) ECMO, cannulae are usually placed in the right common femoral vein for drainage and right internal jugular vein for infusion.[25] Alternatively, a dual-lumen catheter is inserted into the right internal jugular vein, draining blood from the superior and inferior vena cavae and returning it to the right atrium.


ECMO should be performed only by clinicians with training and experience in its initiation, maintenance, and discontinuation. ECMO insertion is typically performed in the operating room setting by a cardiothoracic surgeon. ECMO management is commonly performed by a registered nurse, respiratory therapist, or a perfusionist. Once it has been decided to inititiate ECMO, the patient is anticoagulated with intravenous heparin to prevent thrombus formation from clotting off the oxygenator. Prior to initiation, an IV bolus of heparin is given and measured to ensure that the activated clotting time (ACT) is between 300 and 350 seconds. Once the ACT is between this range, ECMO can be initiated and a heparin drip will be started after as a maintenance dose.[26]


Cannulae can be placed percutaneously by the Seldinger technique, a relatively straightforward and common method for obtaining access to blood vessels, or via surgical cutdown. The largest cannulae that can be placed in the vessels are used in order to maximize flow and minimize shear stress.

ECMO required for complications post-cardiac surgery can be placed directly into the appropriate chambers of the heart or great vessels. Central cannulation via lateral thoracotomy allows patients awaiting lung transplantation to remain unsedated and ambulatory.[27]


Following cannulation and connection to the ECMO circuit, the appropriate amount of blood flow through the ECMO circuit is determined using hemodynamic parameters and physical exam. Goals of maintaining end-organ perfusion via ECMO circuit are balanced with sufficient physiologic blood flow through the heart to prevent stasis and subsequent formation of blood clot.


A respiratory therapist takes a blood sample from a newborn in preparation for ECMO therapy.

Once the initial respiratory and hemodynamic goals have been achieved, the blood flow is maintained at that rate. Frequent assessment and adjustments are facilitated by continuous venous oximetry, which directly measures the oxyhemoglobin saturation of the blood in the venous limb of the ECMO circuit.

Special considerations

VV ECMO is typically used for respiratory failure, while VA ECMO is used for cardiac failure. There are unique considerations for each type of ECMO, which influence management.

Blood flow

Near-maximum flow rates are usually desired during VV ECMO to optimize oxygen delivery. In contrast, the flow rate used during VA ECMO must be high enough to provide adequate perfusion pressure and venous oxyhemoglobin saturation (measured on drainage blood) but low enough to provide sufficient preload to maintain left ventricular output.


Since most people are fluid-overloaded when ECMO is initiated, aggressive diuresis is warranted once the patient is stable on ECMO. Ultrafiltration can be easily added to the ECMO circuit if the patient has inadequate urine output. ECMO "chatter", or instability of ECMO waveforms, represents under-resuscitation and would support cessation of aggressive diuresis or ultrafiltration.

Left ventricular monitoring

Left ventricular output is rigorously monitored during VA ECMO because left ventricular function can be impaired from increased afterload, which can in turn lead to formation of thrombus within the heart.[28][29]

Weaning and discontinuing

For those with respiratory failure, improvements in radiographic appearance, pulmonary compliance, and arterial oxyhemoglobin saturation indicate that the person may be ready to be taken off ECMO support. For those with cardiac failure, enhanced aortic pulsatility correlates with improved left ventricular output and indicates that they may be ready to be taken off ECMO support. If all markers are in good status, the blood flows on the ECMO will be slowly decreased and the patients parameters will be observed during this time to ensure that the patient can tolerate the changes. When the flows are below 2 liters per minute, permanent removal is attempted and the patient is continued to be monitored during this time until the cannulae can be removed.[30]

Veno-venous ECMO liberation trial

VV ECMO trials are performed by eliminating all countercurrent sweep gas through the oxygenator. Extracorporeal blood flow remains constant, but gas transfer does not occur. They are then observed for several hours, during which the ventilator settings that are necessary to maintain adequate oxygenation and ventilation off ECMO are determined as indicated by arterial and venous blood gas results.

Veno-arterial ECMO liberation trial

VA ECMO trials require temporary clamping of both the drainage and infusion lines, while allowing the ECMO circuit to circulate through a bridge between the arterial and venous limbs. This prevents thrombosis of stagnant blood within the ECMO circuit. In addition, the arterial and venous lines should be flushed continuously with heparinized saline or intermittently with heparinized blood from the circuit. In general, VA ECMO trials are shorter in duration than VV ECMO trials because of the higher risk of thrombus formation.


ECMO was developed in the 1950s by John Gibbon, and then by C. Walton Lillehei. The first use for neonates was in 1965.[31][32]

Banning Gray Lary[33] first demonstrated that intravenous oxygen could maintain life. His results were published in Surgical Forum in November 1951.[34] Lary commented on his initial work in a 2007 presentation wherein he writes, "Our research began by assembling an apparatus that, for the first time, kept animals alive while breathing pure nitrogen. This was accomplished with very small bubbles of oxygen injected into the blood stream. These bubbles were made by adding a 'wetting agent' to oxygen being forced through a porcelain filter into the venous blood stream. Shortly after its initial presentation to the American College of Surgeons, this apparatus was reviewed by Walton Lillehei who with DeWall made the first practical heart lung machine that employed a bubble oxygenator. With variations such machines were used for the next twenty years."

Society and culture



Country/territory Continent Hospitals equipped Units
United StatesUnited States North America 264 (in 2019)[36]
CanadaCanada North America 19 (in 2020)[37]
AustraliaAustralia Oceania 146 (in 2020) [38]
BrazilBrazil South America 21 (in 2021)[39]
United KingdomEngland and Wales Europe 5 (in 2020)[40] 15 (in 2020)[40]
Northern IrelandNorthern Ireland Europe 0 (in 2020)[41] 0 (in 2020)[41]
ScotlandScotland Europe 1 (in 2020)[41] 6 (in 2020)[41]
GermanyGermany Europe 214 (in 2020)[42] 755 (in 2020)[43]
PolandPoland Europe 47 (in 2020)[44]
SwedenSweden Europe 7 or more (in 2020)[45]
AlbaniaAlbania Europe 0 (in 2020)[46] 0 (in 2020)[46]
RussiaRussia Europe 124 + 17 (in 2020)[47]
MoscowMoscow Europe 16 (in 2020)[48]
RussiaSaint Petersburg Europe 7 19 (in 2020)[49]
JapanJapan Asia 2208 (in 2020)[50]
ChinaMainland China Asia 400 (approx. in 2020)[51]
Taiwan Taiwan Asia 51 (in 2016)[52] 105 (in 2016)[52]

129 (including rental units, in 2016)[53]


A 2014 study showed that a factor XIIa inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk.[54] Experiments on neonatal animals showed that ECMO treatment can lead to apoptosis of enterocytes, damage of the intestinal mucosal barrier and bacterial translocation. This might explain greater severity of systemic inflammatory response syndrome in neonates.[55] ECMO has also seen its use on cadavers as being able to increase the viability rate of transplanted organs.[56]


  1. ^ "General Guidelines for all ECLS Cases" (PDF). Extracorporeal Life Support Organization. Retrieved April 15, 2015.
  2. ^ Sef, D; Verzelloni Sef, A; Mohite, P; Stock, U; Trkulja, V; Raj, B; Garcia Saez, D; Mahesh, B; De Robertis, F; Simon, A (December 2020). "Utilization of extracorporeal membrane oxygenation in DCD and DBD lung transplants: a 2-year single-center experience". Transplant International. 33 (12): 1788–1798. doi:10.1111/tri.13754. PMID 32989785. S2CID 222162950.
  3. ^ State of New Hampshire Patient Care Protocols v7. New Hampshire: NH Medical Control Board. 2018. p. 2.10.
  4. ^ Ouweneel, DM; Schotborgh, JV; Limpens, J; Sjauw, KD; Engström, AE; Lagrand, WK; Cherpanath, TG; Driessen, AH; de Mol, BA; Henriques, JP (September 19, 2016). "Extracorporeal life support during cardiac arrest and cardiogenic shock: a systematic review and meta-analysis". Intensive Care Medicine. 42 (12): 1922–34. doi:10.1007/s00134-016-4536-8. PMC 5106498. PMID 27647331.
  5. ^ "30 to 39 pct of severe COVID-19 patients discharged from Wuhan hospitals: official - Xinhua | English.news.cn". xinhuanet.com. Retrieved February 16, 2020.
  6. ^ CDC (February 11, 2020). "2019 Novel Coronavirus (2019-nCoV)". Centers for Disease Control and Prevention. Retrieved February 16, 2020.
  7. ^ Melhuish, Thomas M.; Vlok, Ruan; Thang, Christopher; Askew, Judith; White, Leigh (May 2020). "Outcomes of extracorporeal membrane oxygenation support for patients with COVID-19: A pooled analysis of 331 cases". The American Journal of Emergency Medicine. 39: 245–246. doi:10.1016/j.ajem.2020.05.039. PMC 7256518. PMID 32487460.
  8. ^ "LA Times 3-14-2021".
  9. ^ Ben-Nun, Sarah (February 4, 2021). "Pregnant women must not get COVID vaccine in first trimester - Health Min". The Jerusalem Post.
  10. ^ Peek, GJ; Moore, HM; Moore, N; Sosnowski, AW; Firmin, RK (1997). "Extracorporeal membrane oxygenation for adult respiratory failure". Chest. 112 (3): 759–64. doi:10.1378/chest.112.3.759. PMID 9315812.
  11. ^ Lewandowski, K.; Rossaint, R.; Pappert, D.; Gerlach, H.; Slama, K.-J.; Weidemann, H.; Frey, D. J. M.; Hoffmann, O.; Keske, U. (1997). "High survival rate in 122 ARDS patients managed according to a clinical algorithm including extracorporeal membrane oxygenation". Intensive Care Medicine. 23 (8): 819–35. doi:10.1007/s001340050418. PMID 9310799. S2CID 25107418.
  12. ^ Paden, Matthew L.; Conrad, Steven A.; Rycus, Peter T.; Thiagarajan, Ravi R. (April 1, 2017). "Extracorporeal Life Support Organization Registry International Report 2016". ASAIO Journal. 63 (1): 60–67. doi:10.1097/MAT.0000000000000475. PMID 27984321. S2CID 205758344.
  13. ^ Hemmila, Mark R.; Rowe, Stephen A.; Boules, Tamer N.; Miskulin, Judiann; McGillicuddy, John W.; Schuerer, Douglas J.; Haft, Jonathan W.; Swaniker, Fresca; Arbabi, Saman (2004). "Extracorporeal Life Support for Severe Acute Respiratory Distress Syndrome in Adults". Annals of Surgery. 240 (4): 595–605, discussion 605–07. doi:10.1097/01.sla.0000141159.90676.2d. PMC 1356461. PMID 15383787.
  14. ^ Brogan, Thomas V.; Thiagarajan, Ravi R.; Rycus, Peter T.; Bartlett, Robert H.; Bratton, Susan L. (2009). "Extracorporeal membrane oxygenation in adults with severe respiratory failure: A multi-center database". Intensive Care Medicine. 35 (12): 2105–14. doi:10.1007/s00134-009-1661-7. PMID 19768656. S2CID 526020.
  15. ^ Kolla, S; Awad, SS; Rich, PB; Schreiner, RJ; Hirschl, RB; Bartlett, RH (1997). "Extracorporeal life support for 100 adult patients with severe respiratory failure". Annals of Surgery. 226 (4): 544–64, discussion 565–66. doi:10.1097/00000658-199710000-00015. PMC 1191077. PMID 9351722.
  16. ^ Rich, PB; Awad, SS; Kolla, S; Annich, G; Schreiner, RJ; Hirschl, RB; Bartlett, RH (1998). "An approach to the treatment of severe adult respiratory failure". Journal of Critical Care. 13 (1): 26–36. doi:10.1016/S0883-9441(98)90026-0. PMID 9556124.
  17. ^ Ullrich, R; Lorber, C; Röder, G; Urak, G; Faryniak, B; Sladen, RN; Germann, P (1999). "Controlled airway pressure therapy, nitric oxide inhalation, prone position, and extracorporeal membrane oxygenation (ECMO) as components of an integrated approach to ARDS". Anesthesiology. 91 (6): 1577–86. doi:10.1097/00000542-199912000-00007. PMID 10598597.
  18. ^ Lich, Byran (2004). The Manual of Clinical Perfusion (2nd ed.). Fort Myers, Florida: Perfusion.com. ISBN 978-0-9753396-0-2.
  19. ^ Mateen, Farrah J.; Muralidharan, R.; Shinohara, R. T.; Parisi, J. E.; Schears, G. J.; Wijdicks, E. F. (2011). "Neurological Injury in Adults Treated With Extracorporeal Membrane Oxygenation". Archives of Neurology. 68 (12): 1543–49. doi:10.1001/archneurol.2011.209. PMC 7816483. PMID 21825216.
  20. ^ Cornell, Timothy; Wyrick, Polly; Fleming, Geoffrey; Pasko, Deborah; Han, Yong; Custer, Joseph; Haft, Jonathan; Annich, Gail (2007). "A Case Series Describing the Use of Argatroban in Patients on Extracorporeal Circulation". ASAIO Journal. 53 (4): 460–63. doi:10.1097/MAT.0b013e31805c0d6c. PMID 17667231. S2CID 26942284.
  21. ^ Jobe, Alan H. (2004). "Post-conceptional age and IVH in ECMO patients". The Journal of Pediatrics. 145 (2): A2. doi:10.1016/j.jpeds.2004.07.010.
  22. ^ Biffi, Stefano; Di Bella, Stefano; Scaravilli, Vittorio; Peri, Anna Maria; Grasselli, Giacomo; Alagna, Laura; Pesenti, Antonio; Gori, Andrea (July 2017). "Infections during extracorporeal membrane oxygenation: epidemiology, risk factors, pathogenesis and prevention". International Journal of Antimicrobial Agents. 50 (1): 9–16. doi:10.1016/j.ijantimicag.2017.02.025. PMID 28528989.
  23. ^ a b Van Meurs, Krisa; Lally, Kevin; Zwischenberger, Joseph B.; Peek, Giles, eds. (2005). ECMO: Extracorporeal Cardiopulmonary Support in Critical Care. Ann Arbor: Extracorporeal Life Support Organization. ISBN 978-0-9656756-2-8.[page needed]
  24. ^ a b c Madershahian, Navid; Nagib, Ragi; Wippermann, Jens; Strauch, Justus; Wahlers, Thorsten (2006). "A Simple Technique of Distal Limb Perfusion During Prolonged Femoro-Femoral Cannulation". Journal of Cardiac Surgery. 21 (2): 168–69. doi:10.1111/j.1540-8191.2006.00201.x. PMID 16492278. S2CID 11052174.
  25. ^ Wang, Dongfang; Zhou, Xiaoqin; Liu, Xiaojun; Sidor, Bill; Lynch, James; Zwischenberger, Joseph B. (2008). "Wang-Zwische Double Lumen Cannula – Toward a Percutaneous and Ambulatory Paracorporeal Artificial Lung". ASAIO Journal. 54 (6): 606–11. doi:10.1097/MAT.0b013e31818c69ab. PMID 19033774. S2CID 25384012.
  26. ^ Lich, Bryan (2004). The Manual of Clinical Perfusion (2nd ed.). Fort Myers, Florida: Perfusion.com. p. 143. ISBN 978-0-9753396-0-2.
  27. ^ Chierichetti, M.; Santini, A.; Pagan, F.; Crotti, S.; Lissoni, A.; Gattinoni, L. (2012). "ECMO in nonintubated patients as a bridge to lung transplant: Our experience". Critical Care. 16: 97. doi:10.1186/cc10704.
  28. ^ Cohen, Gordon; Permut, Lester (2005). "Decision making for mechanical cardiac assist in pediatric cardiac surgery". Seminars in Thoracic and Cardiovascular Surgery: Pediatric Cardiac Surgery Annual. 8: 41–50. doi:10.1053/j.pcsu.2005.02.004. PMID 15818357.
  29. ^ Vural, Kerem M. (2008). "Ventricular assist device applications". Anadolu Kardiyoloji Dergisi. 8 (Suppl 2): 117–30. PMID 19028644.
  30. ^ Lich, Bryan (2004). The Manual of Clinical Perfusion (2nd ed.). Fort Myers, Florida: Perfusion.com. p. 149. ISBN 978-0-9753396-0-2.
  31. ^ "Pediatric Extracorporeal Membrane Oxygenation". August 3, 2021. Cite journal requires |journal= (help)
  32. ^ Mosier, Jarrod M.; Kelsey, Melissa; Raz, Yuval; Gunnerson, Kyle J.; Meyer, Robyn; Hypes, Cameron D.; Malo, Josh; Whitmore, Sage P.; Spaite, Daniel W. (2015). "Extracorporeal membrane oxygenation (ECMO) for critically ill adults in the emergency department: history, current applications, and future directions". Critical Care. 19: 431. doi:10.1186/s13054-015-1155-7. hdl:10150/621244. PMC 4699333. PMID 26672979.
  33. ^ "B.G. Lary, M.D."
  34. ^ Lary, Banning Gray (November 1951). "Experimental Maintenance of Life by Intravenous Oxygen: Preliminary Report (from the Department of Surgery, University of Iliniois College of Medicine, and St Luke's Hospital, Chicago, Illinois)". Surgical Forum: 30–35 – via W.B. Saunders Company, Philadelphia 1952 (publisher) The Proceedings of the Forum Sessions 37th Clinical Congress of the American College of Surgeons, San Francisco, California, November, 1951.
  35. ^ a b c d e f g "ExtraCorporeal Membrane Oxygenation Market 2020 Recent Trends, Analysis, Business Growth, Share Estimation and Regional Overview Forecast by 2026". MarketWatch. April 16, 2020.
  36. ^ Miracle medical machine ECMO makes heroic rescues, but leaves patients in limbo. USA Today. June 17, 2019.
  37. ^ [1]. ELSO Registry. July 23, 2020.
  38. ^ Litton, Edward; Bucci, Tamara; Chavan, Shaila; Ho, Yvonne Y.; Holley, Anthony; Howard, Gretta; Huckson, Sue; Kwong, Philomena; Millar, Johnny; Nguyen, Nhi; Secombe, Paul; Ziegenfuss, Marc; Pilcher, David (2020). "Surge capacity of intensive care units in case of acute increase in demand caused by COVID ‐19 in Australia" (PDF). Medical Journal of Australia. 212 (10): 463–467. doi:10.5694/mja2.50596. PMC 7264562. PMID 32306408.
  39. ^ [2]. Correio Braziliense. April 5, 2021.
  40. ^ a b Coronavirus: England only has 15 beds for worst respiratory cases. The Guardian. February 27, 2020.
  41. ^ a b c d https://www.euroelso.net/inhalt/uploads/2020/07/ECMO-Map-2020-07-27.pdf
  42. ^ Intensivregister (in German). May 10, 2020
  43. ^ "Intensivregister Tagesreport 2020-05-18" (PDF). DIVI Intensivregister. Retrieved May 20, 2020.[permanent dead link]
  44. ^ Walka z koronawirusem. Ile w Polsce jest urządzeń do wspomagania oddychania? (in Polish). TVN24. March 12, 2020.
  45. ^ Få Ecmo-platser för svårt coronasjuka på Nya Karolinska (in Swedish). Dagens Nyheter. March 10, 2020.
  46. ^ a b Mjeku shqiptar në Gjermani: Ka disa kushte për vetizolimin, në Shqipëri nuk ka aparat ECMO, rreziku është i madh (in Albanian). Ora News. March 12, 2020.
  47. ^ Голикова заверила, что медики в РФ готовы к любому развитию ситуации с COVID-19 (in Russian). Department of health of Moscow [ru]. March 16, 2020.
  48. ^ НОВАЯ ИНФЕКЦИОННАЯ БОЛЬНИЦА СМОЖЕТ ПРИ НЕОБХОДИМОСТИ ПРИНЯТЬ ДО 500 ЧЕЛОВЕК (in Russian). Department of health of Moscow [ru]. March 13, 2020.
  49. ^ "Свободны 400 аппаратов": в Смольном опровергли дефицит ИВЛ в Петербурге (in Russian). Department of health of Moscow [ru]. April 12, 2020.
  50. ^ "国内の病院における人工呼吸器等の取扱台数推計値" [Estimated number of ventilators handled in domestic hospitals] (PDF). Japanese Association for Acute Medicine. May 2020.
  51. ^ 疫情关键时刻救命的ECMO:全国只有400台 为何这么少? (in Chinese). Sina Corp. February 10, 2020
  52. ^ a b "全台爆葉克膜荒 醫護:已無武器可用!". Liberty Times (in Chinese). March 4, 2016. Archived from the original on June 5, 2021. Retrieved June 5, 2021.
  53. ^ "衛福部與衛生局已啟動流感應變醫院及醫療調度機制". 105年衛生福利部新聞/3月新聞 (in Chinese). Department of Medical Affairs, Ministry of Health and Welfare (Taiwan). March 4, 2016. Archived from the original on June 5, 2021. Retrieved June 5, 2021.
  54. ^ Larsson M, Rayzman V, Nolte MW, et al. (January 2014). "A Factor XIIa Inhibitory Antibody Provides Thromboprotection in Extracorporeal Circulation Without Increasing Bleeding Risk". Sci. Transl. Med. 6 (222): 222. doi:10.1126/scitranslmed.3006804. hdl:10616/42281. PMID 24500405. S2CID 5378607.
  55. ^ MohanKumar K (February 2014). "Intestinal epithelial apoptosis initiates gut mucosal injury during extracorporeal membrane oxygenation in the newborn piglet". Lab. Invest. 94 (2): 150–60. doi:10.1038/labinvest.2013.149. PMC 3946757. PMID 24365747.
  56. ^ Magliocca, JF; Magee, JC; Rowe, SA; Gravel, MT; Chenault Rh, 2nd; Merion, RM; Punch, JD; Bartlett, RH; Hemmila, MR (2005). "Extracorporeal support for organ donation after cardiac death effectively expands the donor pool". The Journal of Trauma. 58 (6): 1095–101, discussion 1101–02. doi:10.1097/01.ta.0000169949.82778.df. PMID 15995454.

External links